rift
valley
fever
rvf
one
numer
zoonot
diseas
affect
human
livestock
health
africa
previous
spread
arabian
peninsula
diseas
caus
mosquitoborn
negativestrand
rna
viru
bunyavirida
famili
rvf
viru
first
isol
sheep
kenyan
farm
rvf
viru
infect
wide
rang
domest
wild
anim
patholog
sever
sheep
almost
mortal
abort
rate
occur
newborn
lamb
pregnant
ewe
respect
human
rvf
primarili
occur
follow
close
contact
infect
anim
tissu
bodi
fluid
present
mild
febril
ill
sometim
progress
sever
fatal
manifest
enceph
hemorrhag
although
highli
effect
liveattenu
vaccin
known
clone
avail
livestock
use
rvfendem
countri
licens
livestock
vaccin
avail
use
rvffree
area
europ
current
licens
human
rvf
vaccin
human
anim
recov
infect
rvf
viru
develop
longlast
immun
attribut
acquisit
virusneutr
antibodi
virusneutr
antibodi
mainli
target
gn
gc
envelop
glycoprotein
one
serotyp
encod
segment
rvf
viru
genom
subunit
vaccin
incorpor
one
glycoprotein
induc
virusneutr
respons
may
confer
complet
protect
experiment
rvf
viral
challeng
rodent
livestock
review
thu
develop
gn
gcbase
vaccin
util
vector
establish
human
safeti
profil
could
promis
strategi
futur
human
rvf
vaccin
replicationdefici
adenoviru
vector
far
use
human
clinic
trial
vaccin
plasmodium
falciparum
human
immunodefici
viru
mycobacterium
tuberculosi
hepat
c
viru
influenza
viru
mani
thousand
adult
children
infant
europ
africa
includ
countri
prone
frequent
rvf
epizoot
studi
highlight
excel
safeti
immunogen
profil
adenoviru
vector
human
similar
properti
observ
sever
anim
speci
includ
suscept
rvf
adenovirusvector
vaccin
test
multipl
diseas
develop
effect
adenovirusvector
rvf
vaccin
may
therefor
provid
prophylact
tool
could
use
human
also
anim
speci
suscept
rvf
end
evalu
immunogen
efficaci
replicationdefici
chimpanze
adenoviru
vector
encod
rvf
viru
glycoprotein
gn
gc
balbc
mice
vector
unlik
wide
test
human
adenoviru
type
vector
affect
signific
preexist
antivector
immun
may
limit
vaccin
perform
human
popul
though
phylogenet
classifi
human
adenoviru
e
serotyp
distinct
human
adenoviru
c
mean
antivector
immun
dampen
potenc
vaccin
furthermor
current
clinic
develop
human
influenza
tuberculosi
vaccin
make
good
candid
vector
human
rvf
vaccin
therefor
assess
immunogen
efficaci
vaccin
comparison
vector
encod
gn
gc
strategi
previous
shown
induc
protect
immun
rvf
mice
addit
examin
effect
two
commerci
avail
adjuv
rvf
viru
neutral
antibodi
respons
elicit
vaccin
saponinbas
adjuv
develop
human
use
wherea
squalenebas
oilinwat
emuls
whose
formul
similar
adjuv
licens
human
influenza
vaccin
adjuv
select
use
studi
base
abil
enhanc
antibodi
respons
induc
candid
human
influenza
vaccin
first
compar
rvf
viru
neutral
antibodi
titer
vaccin
regimen
measur
sera
sampl
eight
week
postvaccin
shown
figur
vaccin
elicit
rvf
viru
neutral
antibodi
though
absenc
adjuv
mice
receiv
mount
higher
viru
neutral
titer
vaccin
u
test
p
figur
howev
differ
immunogen
longer
evid
comparison
made
group
group
receiv
coadministr
either
adjuv
kruskalw
test
p
adjuv
significantli
enhanc
rvf
viru
neutral
respons
induc
slight
increas
immunogen
either
adjuv
reach
statist
signific
figur
nevertheless
vaccin
regimen
confer
protect
clinic
diseas
mortal
follow
challeng
lethal
dose
south
african
rvf
viru
strain
tabl
contrast
unvaccin
control
develop
clinic
ill
follow
rvf
viral
challeng
five
six
mice
succumb
infect
next
evalu
vaccineinduc
cell
respons
use
overlap
peptid
n
gener
gn
gc
glycoprotein
rvf
viru
strain
first
peptid
screen
abil
restimul
interferon
gamma
product
splenocyt
obtain
mice
vaccin
measur
enzymelink
immunospot
assay
elispot
pilot
studi
fourteen
peptid
found
restimul
elispot
respons
spot
form
cell
sfc
million
splenocyt
rang
sfc
million
splenocyt
figur
respons
peptid
arbitrari
threshold
shown
figur
sever
fourteen
peptid
elicit
cell
respons
measur
intracellular
cytokin
stain
assay
cell
bare
detect
figur
next
pool
fourteen
peptid
eleven
encompass
predict
major
histocompat
mhc
classi
epitop
addit
file
tabl
made
use
assess
tcell
respons
elicit
vaccin
regimen
frequenc
spotform
splenocyt
measur
elispot
higher
among
mice
receiv
receiv
compar
two
week
u
test
p
figur
eight
week
postvaccin
u
test
p
addit
file
figur
neither
significantli
enhanc
elispot
respons
induc
though
respons
plu
regimen
notabl
higher
figur
addit
file
figur
intracellular
cytokin
stain
assay
peripher
blood
mononuclear
cell
pbmc
sampl
two
week
postvaccin
reveal
robust
cell
respons
mainli
compris
cell
stain
posit
tumor
necrosi
factor
alpha
cytokin
infrequ
interleukin
posit
cell
figur
addit
file
figur
plu
regimen
highest
frequenc
three
cell
subset
figur
predomin
cell
respons
featur
vaccin
regimen
figur
previous
observ
follow
adenoviralvector
vaccin
balbc
mice
recombin
malaria
parasit
antigen
adenoviru
vector
ideal
use
vaccin
zoonot
diseas
rvf
potenti
deploy
human
wide
rang
anim
speci
replicationdefici
chimpanze
adenoviru
vector
particularli
attract
purpos
given
low
preval
neutral
antibodi
human
popul
previous
util
rvf
vaccin
shown
singl
immun
vaccin
confer
protect
rvf
viral
challeng
mice
support
develop
use
futur
human
clinic
trial
suscept
anim
speci
also
confirm
previou
observ
induct
protect
immun
rvf
viral
glycoprotein
mice
though
high
preval
neutral
antibodi
vector
human
may
limit
vaccin
perform
vaccin
could
still
use
anim
inde
vaccin
footandmouth
diseas
recent
licens
livestock
use
unit
state
america
rvf
viru
neutral
antibodi
shown
suffici
protect
rvf
cell
might
also
expect
play
role
immun
clearanc
virusinfect
cell
end
cell
deplet
studi
recent
found
cell
cell
influenc
develop
immun
rvf
neuropatholog
mous
model
follow
infect
attenu
rvf
viru
howev
rel
role
differ
cell
phenotyp
balbc
mous
model
remain
unknown
find
vaccin
readili
induc
rvf
viru
glycoproteinspecif
cell
respons
balbc
mice
observ
recent
studi
use
dna
modifi
vaccinia
viru
ankaravector
gngc
vaccin
robust
immunogen
rvf
viru
neutral
antibodi
cell
present
opportun
dissect
rel
contribut
cell
protect
immun
rvf
balbc
mous
model
final
sought
assess
whether
two
commerci
avail
adjuv
could
enhanc
immunogen
aim
select
vaccin
plu
adjuv
regimen
evalu
vaccin
dosespar
effect
futur
trial
livestock
adjuv
improv
rvf
viru
neutral
antibodi
respons
induc
howev
neither
significantli
enhanc
vaccineinduc
cell
respons
coadministr
result
increas
frequenc
cell
find
may
suggest
could
gener
use
antibodi
induct
chimpanze
adenovirusvector
vaccin
cell
induct
vaccin
requir
studi
greatest
enhanc
viru
neutral
antibodi
titer
adjuv
licens
human
anim
use
futur
studi
livestock
invalu
determin
whether
adjuv
enhanc
magnitud
longev
rvf
viru
neutral
antibodi
respons
induc
ultim
inform
design
subsequ
human
clinic
trial
summari
data
highlight
potenti
util
vector
vaccin
rvf
provid
evid
support
potenti
candid
muchneed
human
rvf
vaccin
hold
promis
livestock
vaccin
like
subunit
rvf
vaccin
develop
allow
differenti
infect
versu
vaccin
anim
diva
use
commerci
avail
diva
test
detect
immun
respons
rvf
viru
compon
gn
gc
nevertheless
better
idea
potenc
vaccin
emerg
studi
target
speci
sheep
goat
cattl
genom
clone
prepar
recombin
life
technolog
ltd
uk
entri
plasmid
contain
segment
rvf
viru
strain
start
fourth
initi
codon
genbank
access
number
base
destin
plasmid
human
adenoviru
type
destin
plasmid
life
technolog
ltd
uk
term
viral
rescu
propag
human
embryon
kidney
cell
result
replicationdefici
virus
purifi
cscl
gradient
ultracentrifug
vector
encod
amino
acid
gn
gc
rvf
viral
polyprotein
control
human
cytomegaloviru
major
immedi
earli
promot
addit
file
figur
n
terminu
gngc
polyprotein
contain
infram
fusion
human
tissu
plasminogen
activ
leader
sequenc
known
enhanc
transgen
express
immunogen
c
terminu
polyprotein
contain
restrict
cell
epitop
syipsaeki
plasmodium
berghei
circumsporozoit
protein
monoclon
antibodi
recognit
sequenc
ipnpllgld
western
blot
confirm
express
respect
antigen
predict
molecular
weight
vector
addit
file
figur
vaccin
regimen
total
femal
balbc
mice
harlan
uk
age
week
old
immun
infecti
unit
respect
vector
phosphatebuff
salin
pb
either
administ
alon
coadminist
one
two
adjuv
invivogen
usa
use
per
mous
isconova
sweden
use
per
mous
immun
intramuscular
perform
isofluoran
anesthesia
total
volum
administ
right
posterior
tibiali
muscl
six
vaccin
regimen
evalu
studi
without
adjuv
ii
plu
adjuv
iii
plu
adjuv
iv
without
adjuv
v
plu
adjuv
vi
plu
adjuv
sampl
immunolog
assay
done
follow
two
week
postvaccin
blood
sampl
taken
eight
mice
per
regimen
intracellular
cytokin
stain
ic
assay
peripher
blood
mononuclear
cell
pbmc
describ
six
mice
cull
time
point
spleen
blood
harvest
interferon
gamma
enzymelink
immunospot
assay
elispot
splenocyt
ic
assay
pbmc
respect
eight
week
postvaccin
blood
sampl
taken
remain
mice
per
regimen
eight
mice
cull
per
regimen
elispot
splenocyt
anoth
hour
remain
mice
mice
per
regimen
togeth
addit
group
six
unvaccin
balbc
mice
challeng
plaqueform
unit
pfu
south
african
rvf
viru
strain
via
intraperiton
rout
describ
primari
endpoint
efficaci
estim
develop
clinic
sign
ill
includ
ruffl
fur
hunch
postur
reduc
activ
describ
monitor
daili
day
also
assess
viraemia
mortal
postchalleng
secondari
endpoint
assess
peak
viraemia
blood
sampl
day
postchalleng
use
viru
isol
surviv
mice
cull
day
followup
anim
procedur
conduct
accord
unit
kingdom
anim
scientif
procedur
act
project
licenc
approv
univers
oxford
anim
care
ethic
review
committe
centro
de
en
sanidad
anim
instituto
nacion
de
agraria
alimentaria
cisainia
committe
biosafeti
ethic
anim
experiment
permit
accord
regulatori
guidelin
european
commun
council
direct
titer
vaccineinduc
rvf
virusneutr
antibodi
measur
previous
describ
briefli
sera
first
heatinactiv
minut
twofold
serial
dilut
made
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fifti
microlit
dilut
serum
mix
equal
volum
medium
contain
pfu
rvf
viru
strain
incub
hour
serumviru
mixtur
transfer
onto
plate
contain
vero
cell
monolay
incub
presenc
hour
cell
fix
stain
solut
contain
formaldehyd
crystal
violet
pb
plaqu
format
score
neutral
titer
defin
highest
serum
dilut
plaqu
format
reduc
rel
cell
incub
rvf
viru
assay
perform
triplic
score
oper
blind
vaccin
regimen
rvf
viral
glycoproteinspecif
cell
measur
elispot
assay
splenocyt
ic
pbmc
strategi
involv
prescreen
overlap
peptid
overlap
amino
acid
span
gn
gc
glycoprotein
rvf
viru
elispot
splenocyt
mice
vaccin
prepar
peptid
pool
compos
peptid
found
restimul
spotform
cell
sfc
million
splenocyt
use
peptid
pool
elispot
ic
assay
splenocyt
pbmc
mice
vaccin
regimen
consid
peptid
synthes
format
mimotop
uk
puriti
use
gn
gc
sequenc
rvf
viru
strain
genbank
access
number
base
stock
peptid
reconstitut
dimethyl
sulfoxid
cell
cultur
media
dmem
contain
fetal
calf
serum
use
dilut
peptid
use
final
concentr
assay
elispot
assay
peptid
restimul
splenocyt
done
hour
ic
assay
peptid
restimul
pbmc
done
hour
frequenc
cell
stain
posit
tumor
necrosi
factor
alpha
interleukin
measur
flow
cytometri
describ
analys
perform
use
graphpad
version
alpha
vaccin
u
test
use
assess
effect
coadministr
either
adjuv
induc
antibodi
cell
respons
kruskalw
test
use
univari
comparison
involv
two
regimen
rvf
rift
valley
fever
interferon
gamma
tumor
necrosi
factor
alpha
interleukin
pbmc
peripher
blood
mononuclear
cell
ic
intracellular
cytokin
stain
elispot
enzymelink
immunospot
dmem
dulbecco
modifi
eagl
medium
mdjd
mgc
scg
avsh
name
inventor
patent
applic
describ
vector
gb
patent
applic
number
author
declar
compet
interest
gmw
mgc
mdjd
design
construct
vaccin
gmw
ar
al
jf
el
gl
aj
kc
ab
perform
anim
studi
western
blot
immunoassay
epitop
predict
sgc
avsh
provid
overal
guidanc
project
design
experi
gmw
wrote
manuscript
critic
input
author
author
read
approv
final
manuscript
